))
The $1 trillion GLP-1 revolution with Rod Wong
Manage episode 459582684 series 3594249
Content provided by RTW Investments, LP, RTW Investments, and LP. All podcast content including episodes, graphics, and podcast descriptions are uploaded and provided directly by RTW Investments, LP, RTW Investments, and LP or their podcast platform partner. If you believe someone is using your copyrighted work without your permission, you can follow the process outlined here https://ppacc.player.fm/legal.
Rod Wong and Stephanie Sirota delve into the transformative potential of GLP-1 drugs, focusing on their impact on obesity and related diseases. Rod shares his insights into the next generation of obesity therapies and the opportunities they present for innovation and investment in the biotech sector.
PODCAST TEAM
Producer: Devon Leaver
Editor: Dominique Guerra
Featuring: Rod Wong, moderated by Stephanie Sirota, Chief Business Officer, and Partner at RTW Investments.
Stay tuned for part two of our discussion on GLP-1s where we welcome Dr. Rekha B. Kumar to the studio at RTW HQ.
FOLLOW US
Love our podcast? Follow us on LinkedIn at RTW Investments, LP and check out our website for the latest updates and insights.
To make sure you never miss an episode, you can subscribe to the RTW podcast on Spotify, Apple Podcasts, Amazon Music, and most other podcast platforms.
CHAPTERS
00:00 - Introductions
00:39 - Understanding the importance of GLP-1s
02:27 - GLPs in the cycle of obesity drug development
05:13 - Public and private company interest in obesity drugs
06:58 - Cost benefits of GLP-1s and their Impact on the healthcare system
10:30 - The value of GLP-1s in the investor space
12:36 - GLP-1s in the international market
16:12 - The expansion of large companies into GLP-1s
18:35 - Thoughts on recent investments and the potential of Kailera Therapeutics
19:52 - Outro and disclaimer
DISCLAIMER
This interview was given by Rod Wong, Managing Partner and Chief Investment Officer of RTW Investments, and moderated by Stephanie Sirota, Chief Business Officer, and Partner at RTW Investments. Statements reflect RTW’s views and opinions as of the date hereof and not as of any future date. All expressions of opinion are subject to change without notice and are not intended to be a forecast of future events or results.
Chapters
1. Introductions (00:00:00)
2. Understanding the importance of GLP-1s (00:00:39)
3. GLPs in the cycle of obesity drug development (00:02:27)
4. Public and private company interest in obesity drugs (00:05:13)
5. Cost benefits of GLP-1s and their Impact on the healthcare system (00:06:58)
6. The value of GLP-1s in the investor space (00:10:30)
7. GLP-1s in the international market (00:12:36)
8. The expansion of large companies into GLP-1s (00:16:12)
9. Thoughts on recent investments and the potential of Kailera Therapeutics (00:18:35)
10. Outro and disclaimer (00:19:52)
7 episodes
Share
